Astellas files experimental AML therapy
Astellas has filed its experimental Acute Myeloid Leukemia (AML) therapy gilteritinib with US regulators, seeking approval for its use to treat FLT3 mutation-positive (FLT3mut+) relapsed or refractory forms of the blood cancer.
Read More
